Comparative Pharmacology
Head-to-head clinical analysis: ZANTAC 25 versus ZANTAC 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZANTAC 25 versus ZANTAC 300.
ZANTAC 25 vs ZANTAC 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking H2 receptors on parietal cells, reducing both basal and stimulated acid production.
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
Ranitidine 150 mg orally twice daily or 50 mg intravenously every 6-8 hours.
300 mg orally once daily at bedtime or 150 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.0 hours (normal renal function); prolonged to 4-5 hours in elderly and up to 6-8 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 2.5–3 hours in patients with normal renal function; prolonged in renal impairment (creatinine clearance <30 mL/min: up to 6–12 hours).
Renal: 70% unchanged via tubular secretion; fecal: 30% as metabolites (N-oxide, S-oxide, desmethyl).
Renal (approximately 30% unchanged active drug via tubular secretion and glomerular filtration); hepatic metabolism to N-oxide, S-oxide, and desmethyl metabolites (about 70% of dose); fecal excretion (minor, <5%).
Category C
Category C
H2 Antagonist
H2 Antagonist